Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (GI002) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Disease Registry for patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (S1500) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of BBI-608 in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CanStem303C) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Combining Talimogene Laherparepvec (T-VEC) and MK-3475 (pembrolizumab) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy (S1607) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (A151216) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (S1400) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Crizotinib vs Placebo for Patients with Tumors Harboring the ALK Fusion Protein (E4512) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Molecular Analysis for Therapy Choice (NCI MATCH) (EAY131) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (INCB-MA-MF-401) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Qualitative Interviews in Patients with Smoldering Multiple Myeloma and Patients with Multiple Myeloma (EVA-21335) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive, HER2 Neg, Breast Cancer (A011502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo-Controlled Study of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, HR+, HER2 Neg, Breast Cancer (S1207) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Abemaciclib Combined with Standard Adj Endocrine Therapy vs Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, HR+, HER2 Neg, Breast Cancer (B58) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NonSmall Cell Lung Cancer (EA5142) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Olaparib vs Placebo as Adjuvant Treatment in Patients with BRCA 1, 2 Mutations and High Risk HER2 Neg Primary Breast Cancer Who Have Completed Definitive Local Treatment and Adj or NeoAdj Chemotherapy (B55) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Tesetaxel Plus Capecitabine vs Capecitabine Alone in Patients with HER2 Neg, HR+, Locally Advanced or Metastatic Brast Cancer Previously Treated with a Taxane (ODO-TE-B301) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (A011401) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer (BR003) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (EA3132) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Bortezomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone Followed by Limited or Indefinite Lenalidomide Maintenance Therapy in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (E1A11) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (N0577) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members